about us
Marshall Edwards is developing novel cancer therapeutics based on the central design of naturally occurring compounds called isoflavones. These compounds are believed to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism – a function critical for the survival of cancer cells.
Our lead programs focus on two groups of small molecules with related but distinct mechanisms of action. The first and most advanced is our NADH oxidase inhibitor program, a family of compounds that includes lead drug candidate ME-143. The second is our novel mitochondrial inhibitor program, which includes lead candidate ME-344. We initiated a Phase I clinical trial of intravenous ME-143 in September 2011.
We own exclusive worldwide rights to all of our drug candidates, including ME-143 and ME-344.
Marshall Edwards is headquartered in San Diego and listed on the Nasdaq Capital Market (Nasdaq: MSHL).
directors
Our board combines decades of drug development, business and Wall Street experience to bring a unique and valuable perspective to the company.
[ Read More ]
management
Our managed team has a deep understanding of oncology drug development, including experience with the world's leading oncology therapeutics.
[ Read more ]